Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sorafenib works in treating patients with angiosarcoma that is locally advanced, metastatic, or unable to be removed by surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the rate of non-progression at 9 months in patients with unresectable, locally advanced, or metastatic angiosarcoma treated with sorafenib tosylate.

Secondary

* Determine the rate of non-progression at 60, 120, and 180 days.
* Determine the median time to progression.
* Determine overall survival.
* Determine the best response rate.
* Determine the clinical and biological factors that predict clinical benefit.
* Evaluate tolerability by NCI CTCAE v3.0.
* Correlate efficacy with plasma expression of genes implicated in controlling angiogenesis.
* Explore the tumor expression of these genes in tissue from a tumor bank.

OUTLINE: This is a multicenter study.

Patients are stratified according to disease type (cutaneous angiosarcoma \[scalp, breast, or soft tissue\] vs visceral angiosarcoma). All patients receive oral sorafenib tosylate twice daily for 9 months in the absence of disease progression or unacceptable toxicity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

stage III adult soft tissue sarcoma stage IV adult soft tissue sarcoma recurrent adult soft tissue sarcoma adult angiosarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sorafenib tosylate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed angiosarcoma

* Locally advanced or metastatic disease
* Unresectable disease
* No Kaposi sarcoma, hemangiopericytoma, or hemangioendothelioma
* Measurable tumor with at least 1 measurable lesion by RECIST criteria
* Tumor in a previously irradiated area must not show progression
* No brain metastases or meningeal tumors (symptomatic or asymptomatic)

PATIENT CHARACTERISTICS:

* WHO performance status 0-2
* Life expectancy ≥ 3 months
* WBC ≥ 3,000/mm³
* ANC ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin ≥ 9 g/dL
* PT or INR and aPTT ≤ 1.5 times upper limit of normal (ULN)

* Anticoagulation treatment with heparin or vitamin K allowed if the above criteria are met
* Liver transaminases ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)
* Total bilirubin ≤ 1.5 times ULN
* Serum creatinine ≤ 1.5 times ULN
* Amylase and lipase ≤ 1.5 times ULN
* Not pregnant or nursing
* Weight loss from pre-disease weight \< 20% over the past 12 months
* Able to swallow
* No active or ischemic coronary artery disease
* No myocardial infarction within the past 6 months
* No NYHA class III-IV cardiac failure
* No uncontrolled hypertension
* No coagulopathy
* No active uncontrolled peptic ulcer
* No patients on renal dialysis
* No active bacterial or fungal infection \> CTCAE v3.0 grade 2
* No HIV or hepatitis B or C positivity
* No chronic unstable illness that could jeopardize patient safety or compliance
* No other progressive or malignant tumor
* No known or suspected allergy to sorafenib tosylate
* No psychological, familial, social, or geographic situations that preclude clinical follow up
* No patients deprived of liberty or under guardianship
* No cardiac arrhythmia requiring antiarrhythmic medication (except beta-blockers or digoxin for chronic atrial fibrillation)
* No epilepsy requiring antiepileptic drugs

PRIOR CONCURRENT THERAPY:

* See Patient Characteristics
* No prior organ or peripheral stem cell transplantation
* No more than 2 prior lines of chemotherapy
* At least 28 days since prior treatment (systemic or major surgery)
* No concurrent therapy for another malignancy
* No concurrent CYP3A inducers (e.g., rifampicin, St. John wort, phenytoin, carbamazepine, phenobarbital, dexamethasone)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicolas Penel, MD

Role: PRINCIPAL_INVESTIGATOR

Centre Oscar Lambret

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Oscar Lambret

Lille, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nicolas Penel, MD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, Robin YM, Bay JO, Piperno-Neumann S, Blay JY, Fournier C. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol. 2014 Sep;9(3):273-7. doi: 10.1007/s11523-013-0299-0. Epub 2013 Nov 12.

Reference Type DERIVED

PMID: 24218035 (View on PubMed)

Valentin T, Fournier C, Penel N, Bompas E, Chaigneau L, Isambert N, Chevreau C. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs. 2013 Dec;31(6):1626-7. doi: 10.1007/s10637-013-0023-z. Epub 2013 Sep 5.

Reference Type DERIVED

PMID: 24005614 (View on PubMed)

Ray-Coquard I, Italiano A, Bompas E, Le Cesne A, Robin YM, Chevreau C, Bay JO, Bousquet G, Piperno-Neumann S, Isambert N, Lemaitre L, Fournier C, Gauthier E, Collard O, Cupissol D, Clisant S, Blay JY, Penel N; French Sarcoma Group (GSF/GETO). Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17(2):260-6. doi: 10.1634/theoncologist.2011-0237. Epub 2012 Jan 27.

Reference Type DERIVED

PMID: 22285963 (View on PubMed)